William Blair equity research analyst Kamil Mielczarek shared with Barron’s why he’s reaffirmed his Outperform rating following the earnings report from Snowflake, the cloud-based solutions provider based out of Bozeman, Montana.
Equity Research
Kamil Mielczarek Shares Insights on Snowflake for Barron’s
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Aardvark Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Aardvark Therapeutics, Inc. (AARD $13.98). Aardvark is advancing ARD-101, an oral therapy that targets bitter taste receptors (TAS2Rs) in the gastrointestinal tract, and ARD-201, a combination of ARD-101 and a DPP-4 inhibitor, for treating Prader-Willi syndrome (PWS) and obesity, respectively.
-
-